EA2234 / STOPGAP II [NCT07001748] (Ongoing trial!)

STOPGAP, 2026 ASCO GI Symposium, 2026 (Part 2)

STOPGAP, 2026 ASCO GI Symposium, 2026 (Part 1)

PERISCOPE II, Lancet Oncology, 2026 (Part 3)

PERISCOPE II, Lancet Oncology, 2026 (Part 2)

PERISCOPE II, Lancet Oncology, 2026 (Part 1)

IKF-AIO-MOONLIGHT Cohort C, EJC, 2026 (Part 3 - Thoughts)

IKF-AIO-MOONLIGHT Cohort C, EJC, 2026 (Part 2)

IKF-AIO-MOONLIGHT Cohort C, EJC, 2026 (Part 1)

IKF-AIO-MOONLIGHT, Nature Commun, 2026 (Part 2)

IKF-AIO-MOONLIGHT, Nature Commun, 2026 (Part 1)

Global burden of cancer attributable to infections in 2024, Lancet Oncology, 2026 (Part 4 - Thoughts)

Global burden of cancer attributable to infections in 2024, Lancet Oncology, 2026 (Part 3 -HepB)

Global burden of cancer attributable to infections in 2024, Lancet Oncology, 2026 (Part 2 – H pylori)

Global burden of cancer attributable to infections in 2024 (Part 1)

EMERALD-3, Lancet Oncology, 2026 (Part 4 - Thoughts)

EMERALD-3, Lancet Oncology, 2026 (Part 3)

EMERALD-3, Lancet Oncology, 2026 (Part 2)

EMERALD-3, Lancet Oncology, 2026 (Part 1)

FDA Approval for Chemo + Zanidatamab +/- Tislelizumab for 1L u-LA/mGEA